首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

市场调查报告书

商品编码

1577005

细胞与基因治疗製造服务市场、机会、成长动力、产业趋势分析与预测，2024-2032

Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月02日 | 出版商:

Global Market Insights Inc. | 英文 227 Pages | 商品交期: 2-3个工作天内

价格

简介目录

受细胞和基因疗法进步以及临床试验数量不断增加的推动，全球细胞和基因疗法製造服务市场到 2023 年价值 59 亿美元，2024 年至 2032 年复合年增长率将扩大到 18.9%。基因编辑和细胞治疗的创新正在扩大治疗的可能性，增加对专业製造的需求。此外，新疗法临床试验的增加增加了对可扩展且合规的製造解决方案的需求。技术进步和积极的临床研究的结合将促进市场成长并推动对先进製造服务的需求。

整个细胞和基因治疗製造服务行业根据类型、适应症、模式、最终用户和地区进行分类。

细胞治疗领域在 2023 年占据 60.6% 的份额，并且在其广泛应用和持续进步的推动下，到 2032 年将以 18.6% 的复合年增长率增长。随着包括 CAR-T 和干细胞治疗在内的细胞疗法在治疗各种疾病方面获得越来越多的关注，对专业製造服务的需求也在增加。细胞疗法所需的复杂性和客製化推动了对复杂製造流程的需求。随着不断的创新和越来越多的临床应用，细胞治疗领域将引领市场。

凭藉其成本效益和专业知识，到 2032 年，合约製造领域的价值将达到 213 亿美元。合约製造组织 (CMO) 提供专业服务，满足细胞和基因疗法从生产到品质控制的复杂且可扩展的需求。他们提供先进技术和监管合规性的能力，以及扩大营运规模的灵活性，使他们成为治疗开发商的重要合作伙伴。随着对这些疗法的需求成长，合约製造领域将主导市场。

由于其先进的医疗基础设施、对生物技术的大量投资以及领先的製药和生物技术公司的高度集中，到 2032 年，北美的复合年增长率将达到 18.1%。该地区健全的监管环境和强大的研发能力进一步巩固了其地位。随着对尖端疗法的需求不断增长，北美现有的专业知识和资源使其成为全球细胞和基因疗法製造服务市场的重要贡献者。

产业生态系统分析
产业影响力
- 成长动力
  - 癌症和其他疾病的盛行率不断增加
  - 增加政府对细胞和基因疗法开发的拨款和支持
  - 增加药品研发支出
- 产业陷阱与挑战
  - 诱变风险高
  - 细胞和基因治疗产品缺乏标准化生产体系
成长潜力分析
监管环境
- 我们
- 加拿大
- 欧洲
技术景观
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
- Thermo Fisher Scientific Inc.
- Boehringer Ingelheim International GmbH
- Merck KGaA
公司市占率分析
主要市场参与者的竞争分析
公司矩阵分析
供应商矩阵分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

主要趋势
细胞疗法
- 同种异体
  - 间质干细胞
  - T细胞
  - 自然杀手细胞
  - 造血干细胞
  - 其他同种异体细胞
- 自体
  - 间质干细胞
  - T细胞
  - 自然杀手细胞
  - 造血干细胞
  - 其他同种异体细胞
基因治疗
- 病毒载体
- 非病毒载体

第 6 章：市场估计与预测：按模式，2018 - 2032

主要趋势
合约製造
内部製造

第 7 章：市场估计与预测：按指标划分，2018 年 - 2032 年

主要趋势
肿瘤疾病
心血管疾病
骨科疾病
传染病
眼科疾病
其他适应症

第 8 章：市场估计与预测：按最终用户，2018 年 - 2032 年

主要趋势
生物製药公司
学术研究机构
医院

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 10 章：公司简介

Boehringer Ingelheim International GmbH
Bluebird Bio, Inc.
Catalent, Inc.
Charles River Laboratories International, Inc.
Merck KGaA
Miltenyi Bioindustry (Miltenyi Biotec)
Samsung Biologics
Takara Bio Inc.
Thermo Fisher Scientific Inc
WuXi AppTec Co., Ltd.

简介目录

Product Code: 5689

The Global Cell & Gene Therapy Manufacturing Services Market, worth USD 5.9 billion in 2023, will expand to an 18.9% CAGR from 2024 to 2032, driven by advancements in cell and gene therapies and the growing number of clinical trials. Innovations in gene editing and cell-based treatments are expanding therapeutic possibilities, increasing demand for specialized manufacturing. Additionally, the rise in clinical trials for new therapies amplifies the need for scalable and compliant manufacturing solutions. This combination of technological progress and active clinical research will boost market growth and drive the demand for advanced manufacturing services.

The overall cell & gene therapy manufacturing services industry is segregated based on type, indication, mode, end use r, and region.

The cell therapy segment captured a 60.6% share in 2023 and will grow at an 18.6% CAGR through 2032, spurred by its widespread application and ongoing advancements. As cell therapies, including CAR-T and stem cell treatments, gain traction in treating various conditions, the demand for specialized manufacturing services increases. The complexity and customization required for cell therapies drive the need for sophisticated manufacturing processes. With continuous innovation and a growing number of clinical applications, the cell therapy segment will lead the market.

The contract manufacturing segment will reach USD 21.3 billion by 2032, attributed to its cost-effectiveness and expertise. Contract manufacturing organizations (CMOs) offer specialized services that address the complex and scalable needs of cell and gene therapies, from production to quality control. Their ability to provide advanced technologies and regulatory compliance, along with the flexibility to scale operations, makes them essential partners for therapy developers. As demand for these therapies grows, the contract manufacturing segment will dominate the market.

North America will register an 18.1% CAGR through 2032 due to its advanced healthcare infrastructure, significant investments in biotechnology, and a high concentration of leading pharmaceutical and biotech companies. The region's robust regulatory environment and strong research and development capabilities further bolster its position. As the demand for cutting-edge therapies grows, North America's established expertise and resources make it a crucial contributor to the global cell & gene therapy manufacturing services market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of cancer and other diseases
  - 3.2.1.2 Increasing government grants and support for development of cell and gene therapies
  - 3.2.1.3 Increasing pharmaceutical R and D spending
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High risk of mutagenesis
  - 3.2.2.2 Lack of standardized production systems for cell and gene therapy products
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Canada
- 3.4.3 Europe
3.5 Technology landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 Thermo Fisher Scientific Inc.
- 4.1.2 Boehringer Ingelheim International GmbH
- 4.1.3 Merck KGaA
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Company matrix analysis
4.5 Vendor matrix analysis
4.6 Competitive positioning matrix
4.7 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Cell therapy
- 5.2.1 Allogenic
  - 5.2.1.1 Mesenchymal stem cells
  - 5.2.1.2 T-cells
  - 5.2.1.3 Natural killer cells
  - 5.2.1.4 Hematopoietic stem cells
  - 5.2.1.5 Other allogeneic cells
- 5.2.2 Autologous
  - 5.2.2.1 Mesenchymal stem cells
  - 5.2.2.2 T-cells
  - 5.2.2.3 Natural killer cells
  - 5.2.2.4 Hematopoietic stem cells
  - 5.2.2.5 Other allogeneic cells
5.3 Gene therapy
- 5.3.1 Viral vectors
- 5.3.2 Non-viral vectors

Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Contract manufacturing
6.3 In-house manufacturing

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Oncology diseases
7.3 Cardiovascular diseases
7.4 Orthopedic diseases
7.5 Infectious diseases
7.6 Ophthalmology diseases
7.7 Other indications

Chapter 8 Market Estimates and Forecast, By End user, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Biopharmaceutical companies
8.3 Academic research institutes
8.4 Hospitals

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa